feed,title,long_url,short_url
Benzinga,Celsion's Ovarian Cancer Immunotherapy Shows 38% Improvement In R0 Resection Rates Versus Control Arm,https://benzinga.com/general/biotech/21/02/19854611/celsions-ovarian-cancer-immunotherapy-shows-38-improvement-in-r0-resection-rates-versus-control-a,
